Sterling Investment Advisors Ltd. Sells 662 Shares of Johnson & Johnson (JNJ)

Sterling Investment Advisors Ltd. reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 18,275 shares of the company’s stock after selling 662 shares during the quarter. Johnson & Johnson accounts for approximately 1.6% of Sterling Investment Advisors Ltd.’s holdings, making the stock its 15th biggest position. Sterling Investment Advisors Ltd.’s holdings in Johnson & Johnson were worth $2,376,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Landmark Financial Advisors LLC grew its stake in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock valued at $259,000 after purchasing an additional 7 shares during the period. Paradigm Financial Advisors LLC grew its stake in shares of Johnson & Johnson by 0.3% during the 2nd quarter. Paradigm Financial Advisors LLC now owns 2,649 shares of the company’s stock valued at $350,000 after acquiring an additional 9 shares during the period. Premier Asset Management LLC grew its stake in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock valued at $363,000 after acquiring an additional 12 shares during the period. Lbmc Investment Advisors LLC grew its stake in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock valued at $492,000 after acquiring an additional 14 shares during the period. Finally, Halbert Hargrove Russell LLC grew its stake in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Halbert Hargrove Russell LLC now owns 3,523 shares of the company’s stock valued at $466,000 after acquiring an additional 15 shares during the period. Institutional investors and hedge funds own 65.70% of the company’s stock.

A number of research analysts recently issued reports on the company. Vetr upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating and set a $152.28 price objective for the company in a research note on Monday. Stifel Nicolaus boosted their price objective on Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a research note on Wednesday, January 24th. BTIG Research reiterated a “sell” rating and set a $110.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the company a “hold” rating in a research note on Monday, January 22nd. Finally, Wells Fargo & Co reiterated an “outperform” rating and set a $160.00 price objective (up from $155.00) on shares of Johnson & Johnson in a research note on Friday, January 12th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $146.16.

Johnson & Johnson (NYSE:JNJ) opened at $130.39 on Tuesday. Johnson & Johnson has a 52 week low of $112.62 and a 52 week high of $148.32. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $369,880.06, a P/E ratio of 18.86, a price-to-earnings-growth ratio of 2.47 and a beta of 0.74.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.72 by $0.02. The business had revenue of $20.20 billion for the quarter, compared to analysts’ expectations of $20.08 billion. Johnson & Johnson had a return on equity of 27.80% and a net margin of 1.70%. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.58 EPS. equities analysts anticipate that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 annualized dividend and a dividend yield of 2.58%. Johnson & Johnson’s dividend payout ratio (DPR) is 861.54%.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by Stock Observer and is owned by of Stock Observer. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.thestockobserver.com/2018/02/06/sterling-investment-advisors-ltd-sells-662-shares-of-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply